Americas was Revvity’s largest region in fiscal 2025, bringing in $505.10M of $2.15B (23%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | — | — | — | ||||||||||||
| Other International | $1.34B | — | — | — | — | ||||||||||||
| Europe | $1.45B | $1.37B | $402.31M | $427.44M | $481.47M | ||||||||||||
| Asia | $1.02B | $505.10M | $434.24M | $451.10M | $438.37M | ||||||||||||
| Americas | $444.46M | $683.17M | $455.83M | $477.88M | $505.10M | ||||||||||||
| China | $449.59M | — | $454.43M | $450.01M | $425.06M | ||||||||||||
| United Kingdom | $357.91M | $136.02M | $125.42M | $112.88M | $126.85M | ||||||||||||
| Germany | — | — | $193.17M | $162.58M | $177.66M | ||||||||||||
| India | — | — | — | — | — | ||||||||||||
| Japan | — | — | — | — | — | ||||||||||||
| France | — | — | — | — | — | ||||||||||||
| Italy | — | — | — | — | — | ||||||||||||
| Korea, Republic Of | — | — | — | — | — | ||||||||||||
| Total | $5.06B | $2.69B | $2.07B | $2.08B | $2.15B |
Revvity brought in $2.15B from its six regions in fiscal 2025, the year ended December 28, 2025. That is less than the $2.86B it reports by major goods/service lines, so these regions do not cover all of its revenue. Americas was the largest at $505.10M (23.4%), ahead of Europe at $481.47M (22.3%) and Asia at $438.37M (20.3%). The other three regions brought in $729.57M combined.
Compared with fiscal 2024, Europe grew fastest, up 12.6% to $481.47M, while China fell the most, down 5.5% to $425.06M.
Revvity stopped reporting Other International as a separate region after fiscal 2022, when it brought in $1.34B.
Life Sciences Solutions was Revvity’s largest revenue line in fiscal 2025, bringing in $1.19B of $2.86B (42%).
| Major goods/service lines | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Life Sciences Solutions | — | $1.28B | $1.20B | $1.19B |
| Immunodiagnostics | $1.11B | $787.39M | $828.63M | $869.91M |
| Life Sciences Reagents | $691.34M | — | — | — |
| Reproductive Health | $516.57M | $504.99M | $527.80M | $555.04M |
| Life Sciences Instruments | $405.55M | — | — | — |
| Applied Genomics | $393.60M | — | — | — |
| Software | — | $178.29M | $200.80M | $236.38M |
| Life Sciences Software | $196.01M | — | — | — |
| Total | $3.31B | $2.75B | $2.76B | $2.86B |
Revvity brought in $2.86B from its four revenue lines in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. Life Sciences Solutions was the largest at $1.19B (41.8%), ahead of Immunodiagnostics at $869.91M (30.5%) and Reproductive Health at $555.04M (19.4%). The remaining revenue line, Software, brought in $236.38M.
Compared with fiscal 2024, Software grew fastest, up 17.7% to $236.38M, while Life Sciences Solutions fell the most, down 0.3% to $1.19B.
Revvity stopped reporting Life Sciences Reagents ($691.34M in fiscal 2023), Life Sciences Instruments ($405.55M in fiscal 2023), Applied Genomics ($393.60M in fiscal 2023) and one other as separate revenue lines.
Diagnostics was Revvity’s largest segment in fiscal 2025, bringing in $1.06B of $1.64B (65%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2021 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Discovery Analytical Solutions | — | — | — | — | |||||||||||
| Discovery &Amp; Analytical Solutions | — | — | — | — | |||||||||||
| Diagnostics | $393.60M | $455.83M | $1.01B | $1.06B | |||||||||||
| Human Health | — | — | — | — | |||||||||||
| Environmental Health | — | — | — | — | |||||||||||
| Life Sciences | $691.34M | $759.78M | $539.02M | $579.88M | |||||||||||
| Total | $1.08B | $1.22B | $1.54B | $1.64B |
Revvity brought in $1.64B from its two segments in fiscal 2025, the year ended December 28, 2025. That is less than the $2.86B it reports by major goods/service lines, so these segments do not cover all of its revenue. Diagnostics was the largest at $1.06B (64.6%), ahead of Life Sciences at $579.88M (35.4%).
Compared with fiscal 2024, Life Sciences grew 7.6% to $579.88M and Diagnostics grew 5.4% to $1.06B.
Revvity (RVTY) reports its revenue by geography, by major goods/service lines and by segment. In fiscal 2025, Americas was its largest region, bringing in $505.10M (23.4% of the total), followed by Europe at $481.47M (22.3%).
Americas was Revvity's largest region in fiscal 2025, bringing in $505.10M, or 23.4% of the $2.15B total across its six regions.
Life Sciences Solutions was Revvity's largest revenue line in fiscal 2025, bringing in $1.19B, or 41.8% of the $2.86B total across its four revenue lines.
Diagnostics was Revvity's largest segment in fiscal 2025, bringing in $1.06B, or 64.6% of the $1.64B total across its two segments.
Among Revvity's regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 12.6% from $427.44M to $481.47M.
Every figure comes from Revvity's annual financial filings, as reported. Each line keeps the name Revvity gives it, and years follow its fiscal calendar.
Revvity's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.